Observation of Silicone Oil Within the Vitreous and Sclera Following Intravitreal Administration of Biotherapeutics Using Insulin Syringes in Cynomolgus Monkeys.

energy-dispersive X-ray spectroscopy intravitreal administration monkey eyes ophthalmic examination silicone oil droplets

Journal

Toxicologic pathology
ISSN: 1533-1601
Titre abrégé: Toxicol Pathol
Pays: United States
ID NLM: 7905907

Informations de publication

Date de publication:
04 2021
Historique:
pubmed: 5 12 2020
medline: 19 8 2021
entrez: 4 12 2020
Statut: ppublish

Résumé

Silicone oil droplets have been reported in the eyes of human patients following intravitreous (IVT) injections with several marketed biotherapeutic products. Intravitreous administration of a novel biotherapeutic in a 14-week cynomolgus monkey study using insulin syringes was associated with 2, non-test-article-related phenomena: "vitreous floater/clear sphere" on indirect ophthalmoscopy and intrascleral "foreign material near injection track" on histopathology. Retrospective analysis of 81 other preclinical studies of IVT administration of novel biotherapeutics found a greater frequency of clear spheres in monkey IVT studies using insulin syringes and formulations containing polysorbate. We were able to correlate microscopic findings of clear circular to oval areas in the sclera near the injection track with an energy-dispersive X-ray spectroscopy (EDS) signal for silicon at the same location in the sclera. These observations provide further evidence that silicone lubricant in insulin syringes/needles is the source of clear spheres noted in the vitreous and foreign material noted near the injection track in the sclera. Although considered inert and toxicologically insignificant, silicone deposition within the eye should form part of the risk-benefit equation in a clinical setting.

Identifiants

pubmed: 33272095
doi: 10.1177/0192623320966543
doi:

Substances chimiques

Insulins 0
Silicone Oils 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

590-597

Auteurs

François Huet (F)

Novartis, 33413Novartis Institutes for BioMedical Research, Preclinical Safety, Cambridge, MA, USA.

Jackie Miller (J)

6728Covance Laboratories Inc, Madison, WI, USA.

Paul E Miller (PE)

70738School of Veterinary Medicine, University of Wisconsin-Madison, WI, USA.
OSOD LLC, Madison, WI, USA.

Chris Hayden (C)

Novartis, 98557Novartis Institutes for BioMedical Research, Preclinical Safety, East Hanover, NJ, USA.

James J Glick (JJ)

Novartis, 98557Novartis Institutes for BioMedical Research, PK Sciences, East Hanover, NJ, USA.

Adam Bentley (A)

Novartis, 98557Novartis Institutes for BioMedical Research, PK Sciences, East Hanover, NJ, USA.

Chris De Benedetto (C)

Novartis, 98557Novartis Institutes for BioMedical Research, Preclinical Safety, East Hanover, NJ, USA.

Leslie E McPherson (LE)

6728Covance Laboratories Inc, Madison, WI, USA.

Oliver C Turner (OC)

Novartis, 98557Novartis Institutes for BioMedical Research, Preclinical Safety, East Hanover, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH